EA200500894A1 - Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы - Google Patents
Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторыInfo
- Publication number
- EA200500894A1 EA200500894A1 EA200500894A EA200500894A EA200500894A1 EA 200500894 A1 EA200500894 A1 EA 200500894A1 EA 200500894 A EA200500894 A EA 200500894A EA 200500894 A EA200500894 A EA 200500894A EA 200500894 A1 EA200500894 A1 EA 200500894A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitor
- nniot
- combination
- cytochrome
- application
- Prior art date
Links
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 title abstract 2
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 title abstract 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43369002P | 2002-12-16 | 2002-12-16 | |
| PCT/EP2003/014224 WO2004054586A1 (en) | 2002-12-16 | 2003-12-15 | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200500894A1 true EA200500894A1 (ru) | 2006-02-24 |
Family
ID=32595224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200500894A EA200500894A1 (ru) | 2002-12-16 | 2003-12-15 | Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040152625A1 (https=) |
| EP (1) | EP1575595A1 (https=) |
| JP (1) | JP2006511538A (https=) |
| KR (1) | KR20050085681A (https=) |
| CN (1) | CN1726041A (https=) |
| AU (1) | AU2003296647A1 (https=) |
| BR (1) | BR0317095A (https=) |
| CA (1) | CA2510143A1 (https=) |
| EA (1) | EA200500894A1 (https=) |
| EC (1) | ECSP055854A (https=) |
| HR (1) | HRP20050557A2 (https=) |
| IL (1) | IL169099A0 (https=) |
| MX (1) | MXPA05005773A (https=) |
| NO (1) | NO20053455L (https=) |
| NZ (1) | NZ541187A (https=) |
| PL (1) | PL376900A1 (https=) |
| RS (1) | RS20050461A (https=) |
| UA (1) | UA81003C2 (https=) |
| WO (1) | WO2004054586A1 (https=) |
| ZA (1) | ZA200502947B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
| US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| ES2539527T3 (es) * | 2005-04-27 | 2015-07-01 | Taimed Biologics, Inc. | Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas |
| CN101405293B (zh) | 2005-11-30 | 2013-03-13 | 中裕新药股份有限公司 | 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法 |
| CN1907138B (zh) * | 2006-08-11 | 2011-01-12 | 华南师范大学 | 一种沙田柚子汁提取物及其提取方法和应用 |
| US8410300B2 (en) | 2006-09-21 | 2013-04-02 | Taimed Biologics, Inc. | Protease inhibitors |
| KR101411889B1 (ko) | 2009-02-27 | 2014-06-27 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염 바이러스 억제제 |
| SG175328A1 (en) * | 2009-04-25 | 2011-11-28 | Hoffmann La Roche | Methods for improving pharmacokinetics |
| US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
| US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| EP4526469A1 (en) | 2022-05-16 | 2025-03-26 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IL111991A (en) * | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| EP0986375A2 (en) * | 1997-04-07 | 2000-03-22 | Triangle Pharmaceuticals Inc. | Use of mkc-442 in combination with other antiviral agents |
| CN1154491C (zh) * | 1998-11-04 | 2004-06-23 | 法玛西雅厄普约翰美国公司 | 用于改善替普拉那维的药物动力学的方法 |
| US6391919B1 (en) * | 2000-01-12 | 2002-05-21 | Bristol-Myers Squibb Pharma Company | Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors |
| TWI270547B (en) * | 2000-06-16 | 2007-01-11 | Boehringer Ingelheim Ca Ltd | Non-nucleoside reverse transcriptase inhibitors |
| JP4391426B2 (ja) * | 2002-09-19 | 2009-12-24 | ベーリンガー インゲルハイム （カナダ） リミテッド | 非ヌクレオシド逆転写酵素インヒビター |
-
2003
- 2003-12-15 MX MXPA05005773A patent/MXPA05005773A/es not_active Application Discontinuation
- 2003-12-15 KR KR1020057011003A patent/KR20050085681A/ko not_active Withdrawn
- 2003-12-15 UA UAA200507057A patent/UA81003C2/uk unknown
- 2003-12-15 JP JP2004560402A patent/JP2006511538A/ja active Pending
- 2003-12-15 RS YUP-2005/0461A patent/RS20050461A/sr unknown
- 2003-12-15 WO PCT/EP2003/014224 patent/WO2004054586A1/en not_active Ceased
- 2003-12-15 NZ NZ541187A patent/NZ541187A/en unknown
- 2003-12-15 US US10/736,301 patent/US20040152625A1/en not_active Abandoned
- 2003-12-15 PL PL376900A patent/PL376900A1/pl not_active Application Discontinuation
- 2003-12-15 EA EA200500894A patent/EA200500894A1/ru unknown
- 2003-12-15 AU AU2003296647A patent/AU2003296647A1/en not_active Abandoned
- 2003-12-15 HR HR20050557A patent/HRP20050557A2/xx not_active Application Discontinuation
- 2003-12-15 BR BR0317095-0A patent/BR0317095A/pt not_active IP Right Cessation
- 2003-12-15 EP EP03813119A patent/EP1575595A1/en not_active Withdrawn
- 2003-12-15 CN CNA2003801063012A patent/CN1726041A/zh active Pending
- 2003-12-15 CA CA002510143A patent/CA2510143A1/en not_active Abandoned
-
2005
- 2005-04-12 ZA ZA200502947A patent/ZA200502947B/en unknown
- 2005-06-09 IL IL169099A patent/IL169099A0/en unknown
- 2005-06-15 EC EC2005005854A patent/ECSP055854A/es unknown
- 2005-07-15 NO NO20053455A patent/NO20053455L/no not_active Application Discontinuation
-
2007
- 2007-10-25 US US11/923,699 patent/US20080096832A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20050557A2 (en) | 2006-05-31 |
| UA81003C2 (en) | 2007-11-26 |
| US20040152625A1 (en) | 2004-08-05 |
| ZA200502947B (en) | 2008-01-30 |
| MXPA05005773A (es) | 2005-08-16 |
| NZ541187A (en) | 2007-12-21 |
| NO20053455L (no) | 2005-08-10 |
| CA2510143A1 (en) | 2004-07-01 |
| BR0317095A (pt) | 2005-10-25 |
| EP1575595A1 (en) | 2005-09-21 |
| RS20050461A (sr) | 2007-08-03 |
| CN1726041A (zh) | 2006-01-25 |
| US20080096832A1 (en) | 2008-04-24 |
| ECSP055854A (es) | 2006-01-16 |
| AU2003296647A1 (en) | 2004-07-09 |
| WO2004054586A1 (en) | 2004-07-01 |
| IL169099A0 (en) | 2007-07-04 |
| KR20050085681A (ko) | 2005-08-29 |
| PL376900A1 (pl) | 2006-01-09 |
| JP2006511538A (ja) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200500894A1 (ru) | Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы | |
| NO20062428L (no) | Kombinasjoner for HCV-behandling | |
| UY35542A (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
| MY138732A (en) | Conjugated complement cascade inhibitors | |
| DE60215787D1 (de) | Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern | |
| EA200500859A1 (ru) | Хинолинилпирролопиразолы | |
| DE602004028841D1 (de) | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c | |
| TW200510425A (en) | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | |
| MXPA04004170A (es) | Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9. | |
| MXPA05006359A (es) | Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos. | |
| EA200200324A1 (ru) | Способы применения селективных ингибиторов обратного захвата серотонина быстрого запуска для лечения половой дисфункции | |
| EA200500406A1 (ru) | Активный ингибитор серинпротеазы hcv | |
| WO2004010937A3 (en) | Method of treating cancer | |
| EA201100506A1 (ru) | Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином | |
| DE60327557D1 (de) | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie | |
| EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
| EA200870086A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства | |
| EA200870090A1 (ru) | Применение производных сульфамида, включающих гетероцикл, конденсированный с бензольным кольцом, для лечения депрессии | |
| EA200200502A1 (ru) | Способ введения ингибитора фосфодиэстеразы 4 | |
| EA200300844A1 (ru) | Использование ингибиторов il-18 для лечения и/или профилактики заболевания сердца | |
| ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
| DK1949893T3 (da) | Quinazolinderivater, der kan anvendes til behandling af perifer arteriel sygdom og som phosphodiesteraseinhibitorer | |
| EA200600989A1 (ru) | Применение габоксадола для лечения бессонницы | |
| EA200000513A1 (ru) | Комбинированная терапия для лечения спид | |
| EA200501259A1 (ru) | Комбинированное применение фибрата и орлистата для лечения ожирения |